Author: Bella Hayes

By Nandita Bose and Kanishka Singh (Reuters) – Apple (NASDAQ:) CEO Tim Cook will meet Donald Trump on Friday night at the U.S. president-elect’s Mar-a-Lago resort in Florida, a source familiar with the matter told Reuters. Business leaders have attempted to establish a positive rapport with Trump since his election win in November. Meta (NASDAQ:) Platforms and Amazon (NASDAQ:) have each donated $1 million to Trump’s inaugural fund. Bank of America (NYSE:), the second-largest U.S. lender, also plans to contribute to Trump’s inaugural committee but has yet to decide on the amount. Trump will take office in January. He said…

Read More

New York, New York–(Newsfile Corp. – December 13, 2024) – WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of PACS Group Inc. (NYSE: PACS) of (i) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the “Registration Statement”) in connection with the Company’s April 11, 2024 initial public offering (“IPO”); (ii) securities between April 11, 2024 and November 5, 2024, both dates inclusive (the “Class Period”); and/or (iii) common stock pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company’s September 2024 secondary public offering (“SPO”), of the…

Read More

Silvana Battaglia, a director at agilon health, inc. (NYSE:AGL), recently purchased 25,062 shares of the company’s common stock, amounting to a total value of $50,269. The shares were acquired at a weighted average price of $2.0058 per share, with transactions occurring within a range of $1.995 to $2.010. The purchase comes as the stock has seen a significant decline, down about 82% over the past year, though it has shown signs of recovery with a 2.3% gain in the past week. Following this acquisition, Battaglia holds a total of 66,144 shares, which include restricted stock units. According to InvestingPro analysis,…

Read More

Saiyed Atiq Raza, a director at Arteris, Inc. (NASDAQ:AIP), a $401 million market cap semiconductor company with impressive 89% gross margins, recently sold shares. According to a Form 4 filing with the Securities and Exchange Commission, Raza executed the sales over two days. InvestingPro data shows the stock trading near its 52-week high of $10.24, having gained over 72% year-to-date. On December 11, he sold 2,400 shares at a weighted average price of approximately $10.01 per share. The next day, December 12, he sold an additional 16,950 shares at a weighted average price of $10.12 per share. The total value…

Read More

Control Empresarial de Capitales S.A. de C.V., a significant shareholder in PBF Energy Inc. (NYSE:), has increased its stake in the company with the purchase of additional shares. According to a recent SEC filing, Control Empresarial acquired a total of 285,000 Class A common shares over two days, December 11 and 12. The timing is notable as PBF currently trades near its 52-week low of $27.94, with InvestingPro data showing the stock has declined over 30% year-to-date. The shares were bought at a weighted average price of $30.0401 on December 11 and $29.5803 on December 12. These transactions, totaling approximately…

Read More

Xue Bing, Executive Vice President of Worldwide Sales and Business Development at Alpha & Omega Semiconductor Ltd (NASDAQ:AOSL), recently sold 1,883 common shares of the company. The transaction, which took place on December 12, 2024, was executed at a price of $47.38 per share, amounting to a total value of $89,216. Following this sale, Xue Bing retains ownership of 127,103 shares, which includes various unvested shares subject to performance and service-based vesting conditions. The sale was conducted under a Rule 10b5-1 trading plan, which had been adopted on September 3, 2024. In other recent news, Alpha & Omega Semiconductor has…

Read More

David A. Sachs, a director at Terex Corp (NYSE:), has recently made significant stock purchases, according to a recent SEC filing. On December 11 and 12, Sachs acquired a total of 20,000 shares of Terex common stock, with purchase prices ranging from $50.16 to $51.30 per share. The transactions, conducted through a family LLC, amounted to a total value of approximately $1,014,600. The purchases come as Terex, with a market capitalization of $3.31 billion, trades near its 52-week low and at an attractive P/E ratio of 7.2. According to InvestingPro analysis, the stock appears undervalued based on its Fair Value…

Read More

Fahmy Sameh, a director at Norfolk Southern Corp (NYSE:NSC), a railroad giant with a market capitalization of $56 billion, recently purchased 350 shares of the company’s common stock. According to InvestingPro data, the company currently trades at a P/E ratio of 23.1x. The transaction, dated December 12, 2024, was executed at a price of $249.371 per share, amounting to a total investment of $87,279. Following this acquisition, Sameh’s direct ownership of Norfolk Southern shares increased to 10,350 shares. The transaction was filed with the SEC on December 13, 2024. Norfolk Southern has maintained dividend payments for 43 consecutive years, with…

Read More

By Echo Wang (Reuters) -Wall Street’s main indexes edged lower on Friday as rising government bond yields weighed on investor sentiment, while an optimistic forecast from Broadcom (NASDAQ:) helped sustain enthusiasm around artificial intelligence. Broadcom forecast quarterly revenue surpassing Wall Street expectations and predicted robust growth in demand for its custom AI chips over the next few years. The optimistic outlook propelled the company’s shares nearly 20% higher, pushing its market capitalization past $1 trillion for the first time. Chip stocks were mixed, with Broadcom rival Marvell Technology (NASDAQ:) rising 9.4%, while AI bellwether Nvidia (NASDAQ:) reversed gains and was…

Read More

In a turbulent market environment, TCRT stock has reached a 52-week low, trading at $1.92, with a market capitalization of just $3.14 million. The company’s beta of -0.44 indicates its stock often moves contrary to broader market trends. This price level reflects a significant downturn for the company, which has seen its shares struggle amidst broader industry and economic pressures. InvestingPro data reveals an alarming year-to-date decline of 80.39%. Over the past year, TCRT’s performance has mirrored the challenging journey of many biotech firms, with ZIOPHARM Oncology (NASDAQ:), a sector peer, experiencing a staggering 1-year change of -74.43%. Investors are…

Read More